UK population based study to predict impact of HPV vaccination

Journal of Clinical Virology

Volumn 59, Issue 2, 2014, Pages 109-114

  Hibbitts, Sam ^a   Tristram, Amanda ^a   Beer, Helen ^b   McRea, Jane ^b   Rose, Bryan ^b   Hauke, Anne ^b   Nuttall, Dave ^b   Dallimore, Nick ^b   Newcombe, Robert G ^a   Fiander, Alison ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b PUBLIC HEALTH WALES   (United Kingdom)

Author keywords

Cervarix and Gardasil; Cervical screening; HPV vaccination; Human papillomavirus (HPV)

Indexed keywords

WART VIRUS VACCINE;

ADULT; ALPHAPAPILLOMAVIRUS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS PROTECTION; DYSKARYOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL MONITORING; FEMALE; GENOTYPE; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 51; INFECTION PREVENTION; INFECTION RISK; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MIXED INFECTION; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; SCREENING; SOCIAL ISOLATION; UNITED KINGDOM; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; YOUNG ADULT;

CERVARIX AND GARDASIL; CERVICAL SCREENING; HPV VACCINATION; HUMAN PAPILLOMAVIRUS (HPV);

CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; FEMALE; GENOTYPE; GREAT BRITAIN; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; PROSPECTIVE STUDIES; VACCINATION; YOUNG ADULT;

EID: 84892979726     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.12.002     Document Type: Article

References (22)

1. Hibbitts S., Jones J., Powell N., Dallimore N., McRea J., Beer H., et al. Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study. Br J Cancer 2008, 99:1929-1933.
2. Bosch F.X., Schwarz E., Boukamp P., Fusenig N.E., Bartsch D., zur Hausen H. Suppression in vivo of human papillomavirus type 18 E6-E7 gene expression in nontumorigenic HeLa X fibroblast hybrid cells. J Virol 1990, 64:4743-4754.
3. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
4. Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 2000, 19:1-5.
5. Powell N., Boyde A., Tristram A., Hibbitts S., Fiander A. The potential impact of human papillomavirus vaccination in contemporary cytologically screened populations may be underestimated: an observational retrospective analysis of invasive cervical cancers. Int J Cancer 2009, 125:2425-2427.
6. Peto J., Gilham C., Fletcher O., Matthews F.E. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004, 364:249-256.
7. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010, 11:249-257.
8. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119:1095-1101.
9. Kitchener H.C., Gilham C., Sargent A., Bailey A., Albrow R., Roberts C., et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial. Eur J Cancer 2011, 47:864-871.
10. Stoler M.H., Wright T.C., Sharma A., Apple R., Gutekunst K., Wright T.L. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011, 135:468-475.
11. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
12. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
13. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
14. Wales P.H. Vaccine uptake in children in Wales July to September 2012. Coverage of Vaccination Evaluated Rapidly (COVER) 2012, The National Publich Health Service for Wales, Cardiff. P.H. Wales (Ed.).
15. Hibbitts S., Rieck G.C., Hart K., Powell N.G., Beukenholdt R., Dallimore N., et al. Human papillomavirus infection: an anonymous prevalence study in South Wales, UK. Br J Cancer 2006, 95:226-232.
16. Howell-Jones R., Bailey A., Beddows S., Sargent A., de Silva N., Wilson G., et al. Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 2010, 103:209-216.
17. Cuschieri K.S., Cubie H.A., Whitley M.W., Seagar A.L., Arends M.J., Moore C., et al. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004, 57:68-72.
18. Kitchener H.C., Almonte M., Wheeler P., Desai M., Gilham C., Bailey A., et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006, 95:56-61.
19. Jacobs M.V., Snijders P.J., van den Brule A.J., Helmerhorst T.J., Meijer C.J., Walboomers J.M. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997, 35:791-795.
20. Newcombe R.G. Propagating imprecision: combining confidence intervals from independent sources. Communications in Statistics - Theory & Methods 2011, 40:3154-3180.
21. Miettinen O., Nurminen M. Comparative analysis of two rates. Stat Med 1985, 4:213-226.
22. Jit M., Chapman R., Hughes O., Choi Y.H. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775.